| Year |
Citation |
Score |
| 2024 |
Higginbotham L, Scorr LM, Parra SP, Sommerfeld B, Jinnah HA, Factor SA. Prevalence and clinical features of cervical dystonia in Parkinson's disease. Parkinsonism & Related Disorders. 127: 107114. PMID 39197296 DOI: 10.1016/j.parkreldis.2024.107114 |
0.32 |
|
| 2024 |
Kassubek J, Factor SA, Balaguer E, Schwarz J, Chaudhuri KR, Isaacson SH, Wu S, Denecke Muhr C, Kulisevsky J. Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson's disease complicated by OFF episodes: a phase 3, open-label study. Journal of Neurology. PMID 38546829 DOI: 10.1007/s00415-024-12323-2 |
0.331 |
|
| 2023 |
Huddleston DE, Chen X, Hwang K, Langley J, Tripathi R, Tucker K, McKay JL, Hu X, Factor SA. Neuromelanin-sensitive MRI correlates of cognitive and motor function in Parkinson's disease with freezing of gait. Frontiers in Dementia. 2: 1215505. PMID 39082000 DOI: 10.3389/frdem.2023.1215505 |
0.322 |
|
| 2023 |
Gong NJ, Clifford GD, Esper CD, Factor SA, McKay JL, Kwon H. Classifying Tremor Dominant and Postural Instability and Gait Difficulty Subtypes of Parkinson's Disease from Full-Body Kinematics. Sensors (Basel, Switzerland). 23. PMID 37837160 DOI: 10.3390/s23198330 |
0.334 |
|
| 2023 |
Virmani T, Landes RD, Pillai L, Glover A, Larson-Prior L, Prior F, Factor SA. Gait Declines Differentially in, and Improves Prediction of, People with Parkinson's Disease Converting to a Freezing of Gait Phenotype. Journal of Parkinson's Disease. PMID 37522218 DOI: 10.3233/JPD-230020 |
0.339 |
|
| 2023 |
Huddleston DE, Chen X, Hwang K, Langley J, Tripathi R, Tucker K, McKay JL, Hu X, Factor SA. Neuromelanin-sensitive MRI correlates of cognitive and motor function in Parkinson's disease with freezing of gait. Medrxiv : the Preprint Server For Health Sciences. PMID 37461735 DOI: 10.1101/2023.07.04.23292227 |
0.322 |
|
| 2023 |
McKay JL, Nye J, Goldstein FC, Sommerfeld B, Smith Y, Weinshenker D, Factor SA. Levodopa responsive freezing of gait is associated with reduced norepinephrine transporter binding in Parkinson's disease. Neurobiology of Disease. 179: 106048. PMID 36813207 DOI: 10.1016/j.nbd.2023.106048 |
0.354 |
|
| 2022 |
Bliwise DL, Karroum EG, Greer SA, Factor SA, Trotti LM. Restless Legs Symptoms and Periodic Leg Movements in Sleep Among Patients with Parkinson's Disease. Journal of Parkinson's Disease. PMID 35311713 DOI: 10.3233/JPD-213100 |
0.376 |
|
| 2021 |
Bohnen NI, Costa RM, Dauer WT, Factor SA, Giladi N, Hallett M, Lewis SJG, Nieuwboer A, Nutt JG, Takakusaki K, Kang UJ, Przedborski S, Papa SM. Discussion of Research Priorities for Gait Disorders in Parkinson's Disease. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 34939221 DOI: 10.1002/mds.28883 |
0.307 |
|
| 2020 |
Caughman CY, Factor S. A critical review of apomorphine hydrochloride sublingual film for the treatment of Parkinson's disease 'OFF' episodes. Expert Review of Neurotherapeutics. 21: 169-177. PMID 33227223 DOI: 10.1080/14737175.2020.1855145 |
0.386 |
|
| 2020 |
Perez Parra S, McKay JL, Factor SA. Diphasic Worsening of Freezing of Gait in Parkinson's Disease. Movement Disorders Clinical Practice. 7: 325-328. PMID 32258233 DOI: 10.1002/mdc3.12918 |
0.312 |
|
| 2020 |
Wallace DM, Wohlgemuth WK, Trotti LM, Amara AW, Malaty IA, Factor SA, Nallu S, Wittine L, Hauser RA. Practical Evaluation and Management of Insomnia in Parkinson's Disease: A Review. Movement Disorders Clinical Practice. 7: 250-266. PMID 32258222 DOI: 10.1002/mdc3.12899 |
0.34 |
|
| 2019 |
Olanow CW, Factor SA, Espay AJ, Hauser RA, Shill HA, Isaacson S, Pahwa R, Leinonen M, Bhargava P, Sciarappa K, Navia B, Blum D. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. The Lancet. Neurology. PMID 31818699 DOI: 10.1016/S1474-4422(19)30396-5 |
0.345 |
|
| 2019 |
Lucas McKay J, Goldstein FC, Sommerfeld B, Bernhard D, Perez Parra S, Factor SA. Freezing of Gait can persist after an acute levodopa challenge in Parkinson's disease. Npj Parkinson's Disease. 5: 25. PMID 31799377 DOI: 10.1038/s41531-019-0099-z |
0.341 |
|
| 2019 |
McKay JL, Hackney ME, Factor SA, Ting LH. Lower Limb Rigidity Is Associated with Frequent Falls in Parkinson's Disease. Movement Disorders Clinical Practice. 6: 446-451. PMID 31392245 DOI: 10.1002/Mdc3.12784 |
0.338 |
|
| 2019 |
Factor SA. Parkinson's Disease: Motor Fluctuations. Current Treatment Options in Neurology. 1: 21-32. PMID 11096692 DOI: 10.1007/S11940-999-0029-1 |
0.447 |
|
| 2017 |
Vaughan CP, Prizer LP, Vandenberg AE, Goldstein FC, Trotti LM, Hermida AP, Factor SA. A Comprehensive Approach to Care in Parkinson's Disease Adds Quality to the Current Gold Standard. Movement Disorders Clinical Practice. 4: 743-749. PMID 30363392 DOI: 10.1002/mdc3.12508 |
0.329 |
|
| 2017 |
Factor SA, Scullin MK, Freeman A, Bliwise DL, McDonald WM, Goldstein FC. Affective Correlates of Psychosis in Parkinson's Disease. Movement Disorders Clinical Practice. 4: 225-230. PMID 28944257 DOI: 10.1002/Mdc3.12381 |
0.38 |
|
| 2017 |
Factor SA, McDonald WM, Goldstein FC. The role of neurotransmitters in the development of Parkinson's disease-related psychosis. European Journal of Neurology. PMID 28758318 DOI: 10.1111/ene.13376 |
0.326 |
|
| 2017 |
Fox SH, Metman LV, Nutt JG, Brodsky M, Factor SA, Lang AE, Pope LE, Knowles N, Siffert J. Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 28370447 DOI: 10.1002/Mds.26976 |
0.352 |
|
| 2017 |
Hill-Burns EM, Debelius JW, Morton JT, Wissemann WT, Lewis MR, Wallen ZD, Peddada SD, Factor SA, Molho E, Zabetian CP, Knight R, Payami H. Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 28195358 DOI: 10.1002/Mds.26942 |
0.367 |
|
| 2016 |
Hermida AP, Janjua AU, Glass OM, Vaughan CP, Goldstein F, Trotti LM, Factor SA. A case of lithium-induced parkinsonism presenting with typical motor symptoms of Parkinson's disease in a bipolar patient. International Psychogeriatrics / Ipa. 1-4. PMID 27517671 DOI: 10.1017/S1041610216001101 |
0.364 |
|
| 2015 |
Biglan KM, Shoulson I, Kieburtz K, Oakes D, Kayson E, Shinaman MA, Zhao H, Romer M, Young A, Hersch S, Penney J, Marder K, Paulsen J, Quaid K, ... ... Factor S, et al. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. Jama Neurology. 1-9. PMID 26569098 DOI: 10.1001/Jamaneurol.2015.2736 |
0.504 |
|
| 2014 |
Factor SA, Scullin MK, Sollinger AB, Land JO, Wood-Siverio C, Zanders L, Freeman A, Bliwise DL, Goldstein FC. Freezing of gait subtypes have different cognitive correlates in Parkinson's disease. Parkinsonism & Related Disorders. 20: 1359-64. PMID 25446341 DOI: 10.1016/J.Parkreldis.2014.09.023 |
0.334 |
|
| 2014 |
Hauser RA, Isaacson S, Clinch T, Ellenbogen A, Silver D, Struck L, Gil R, Pappert E, Jankovic J, Goldstein S, LeWitt P, Hull K, Thomas M, Danisi F, Factor S, et al. Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection Parkinsonism and Related Disorders. 20: 1171-1176. PMID 25239603 DOI: 10.1016/j.parkreldis.2014.08.010 |
0.338 |
|
| 2014 |
Moonen AJ, Wijers A, Leentjens AF, Christine CW, Factor SA, Juncos J, Lyness JM, Marsh L, Panisset M, Pfeiffer R, Rottenberg D, Serrano Ramos C, Shulman L, Singer C, Slevin J, et al. Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's disease. Parkinsonism & Related Disorders. 20: 644-6. PMID 24679737 DOI: 10.1016/j.parkreldis.2014.02.025 |
0.311 |
|
| 2013 |
Silver M, Factor SA. Valproic acid-induced parkinsonism: levodopa responsiveness with dyskinesia. Parkinsonism & Related Disorders. 19: 758-60. PMID 23632325 DOI: 10.1016/j.parkreldis.2013.03.016 |
0.335 |
|
| 2012 |
Revuelta GJ, Uthayathas S, Wahlquist AE, Factor SA, Papa SM. Non-human primate FOG develops with advanced parkinsonism induced by MPTP Treatment. Experimental Neurology. 237: 464-9. PMID 22967858 DOI: 10.1016/j.expneurol.2012.07.021 |
0.326 |
|
| 2012 |
Bliwise DL, Trotti LM, Wilson AG, Greer SA, Wood-Siverio C, Juncos JJ, Factor SA, Freeman A, Rye DB. Daytime alertness in Parkinson's disease: potentially dose-dependent, divergent effects by drug class. Movement Disorders : Official Journal of the Movement Disorder Society. 27: 1118-24. PMID 22753297 DOI: 10.1002/Mds.25082 |
0.309 |
|
| 2012 |
Smith Y, Wichmann T, Factor SA, DeLong MR. Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 37: 213-46. PMID 21956442 DOI: 10.1038/npp.2011.212 |
0.363 |
|
| 2011 |
Robottom BJ, Factor SA, Weiner WJ. Movement disorders emergencies Part 2: hyperkinetic disorders. Archives of Neurology. 68: 719-24. PMID 21670395 DOI: 10.1001/archneurol.2011.117 |
0.433 |
|
| 2011 |
Robottom BJ, Weiner WJ, Factor SA. Movement disorders emergencies. Part 1: Hypokinetic disorders. Archives of Neurology. 68: 567-72. PMID 21555633 DOI: 10.1001/archneurol.2011.84 |
0.494 |
|
| 2010 |
Cheng EM, Tonn S, Swain-Eng R, Factor SA, Weiner WJ, Bever CT. Quality improvement in neurology: AAN Parkinson disease quality measures: report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology. Neurology. 75: 2021-7. PMID 21115958 DOI: 10.1212/WNL.0b013e3181ff96dd |
0.443 |
|
| 2009 |
Weiner W, Ahlskog E, Factor S, Suchowersky O, Reich S. Initiating therapy in Parkinson's disease Annals of Neurology. 65: 480-481. PMID 19399873 DOI: 10.1002/Ana.21667 |
0.568 |
|
| 2009 |
Hamza T, Factor S, Molho E, Montimurro J, Pratt D, Rosen A, Higgins D, Payami H. P2.110 Evidence for association of high-dose levodopa therapy with intellectual and psychiatric complications of Parkinson's disease Parkinsonism & Related Disorders. 15: S119. DOI: 10.1016/S1353-8020(09)70461-4 |
0.325 |
|
| 2008 |
Factor SA. The clinical spectrum of freezing of gait in atypical parkinsonism. Movement Disorders : Official Journal of the Movement Disorder Society. 23: S431-8. PMID 18668624 DOI: 10.1002/mds.21849 |
0.342 |
|
| 2008 |
Hutter CM, Samii A, Factor SA, Nutt JG, Higgins DS, Bird TD, Griffith A, Roberts JW, Leis BC, Montimurro JS, Kay DM, Edwards KL, Payami H, Zabetian CP. Lack of evidence for an association between UCHL1 S18Y and Parkinson's disease. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 15: 134-9. PMID 18093156 DOI: 10.1111/J.1468-1331.2007.02012.X |
0.326 |
|
| 2008 |
Factor SA, Lang AE, Weiner WJ. Preface Drug Induced Movement Disorders: Second Edition. xiii-xiv. DOI: 10.1002/9780470753217 |
0.36 |
|
| 2007 |
Esper CD, Weiner WJ, Factor SA. Progressive supranuclear palsy. Reviews in Neurological Diseases. 4: 209-16. PMID 18195676 |
0.512 |
|
| 2007 |
Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, Elmer LW, Truong DD, Earl NL. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology. 68: 1108-15. PMID 17404192 DOI: 10.1212/01.Wnl.0000258660.74391.C1 |
0.342 |
|
| 2007 |
Ravina B, Marder K, Fernandez HH, Friedman JH, McDonald W, Murphy D, Aarsland D, Babcock D, Cummings J, Endicott J, Factor S, Galpern W, Lees A, Marsh L, Stacy M, et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Movement Disorders : Official Journal of the Movement Disorder Society. 22: 1061-8. PMID 17266092 DOI: 10.1002/Mds.21382 |
0.328 |
|
| 2007 |
Nichols WC, Marek DK, Pauciulo MW, Pankratz N, Halter CA, Rudolph A, Shults CW, Wojcieszek J, Foroud T, Shults C, Marshall F, Oakes D, Shinaman A, Marder K, Conneally PM, ... ... Factor S, et al. R1514Q substitution in Lrrk2 is not a pathogenic Parkinson's disease mutation Movement Disorders. 22: 254-257. PMID 17149721 DOI: 10.1002/Mds.21233 |
0.389 |
|
| 2007 |
Factor SA. Fatal Parkinsonism-hyperpyrexia syndrome in a Parkinson's disease patient while actively treated with deep brain stimulation. Movement Disorders : Official Journal of the Movement Disorder Society. 22: 148-9. PMID 17080464 DOI: 10.1002/mds.21172 |
0.328 |
|
| 2007 |
Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H, Hallett M, Miyasaki J, Stevens J, Weiner WJ. Appendix D: Practice parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidenced-based review): Report of the Quality Standards Subcommitte of the American Academy of Neurology Continuum Lifelong Learning in Neurology. 13: 177-189. |
0.507 |
|
| 2006 |
Pankratz N, Pauciulo MW, Elsaesser VE, Marek DK, Halter CA, Rudolph A, Shults CW, Foroud T, Nichols WC, Shults C, Marshall F, Oakes D, Shinaman A, Marder K, Conneally PM, ... ... Factor S, et al. Mutations in LRRK2 other than G2019S are rare in a north-American based sample of familial Parkinson's didease Movement Disorders. 21: 2257-2260. PMID 17078063 DOI: 10.1002/Mds.21162 |
0.325 |
|
| 2006 |
Friedman JH, Berman RM, Goetz CG, Factor SA, Ondo WG, Wojcieszek J, Carson WH, Marcus RN. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 2078-81. PMID 17013906 DOI: 10.1002/mds.21091 |
0.406 |
|
| 2006 |
Zabetian CP, Hutter CM, Yearout D, Lopez AN, Factor SA, Griffith A, Leis BC, Bird TD, Nutt JG, Higgins DS, Roberts JW, Kay DM, Edwards KL, Samii A, Payami H. LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. American Journal of Human Genetics. 79: 752-8. PMID 16960813 DOI: 10.1086/508025 |
0.354 |
|
| 2006 |
Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H, Hallett M, Miyasaki J, Stevens J, Weiner WJ. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 66: 983-95. PMID 16606909 DOI: 10.1212/01.wnl.0000215250.82576.87 |
0.504 |
|
| 2006 |
Huber VC, Mondal T, Factor SA, Seegal RF, Lawrence DA. Serum antibodies from Parkinson's disease patients react with neuronal membrane proteins from a mouse dopaminergic cell line and affect its dopamine expression. Journal of Neuroinflammation. 3: 1. PMID 16426448 DOI: 10.1186/1742-2094-3-1 |
0.31 |
|
| 2004 |
Factor SA, Molho ES. Threatening auditory hallucinations and Cotard syndrome in Parkinson disease. Clinical Neuropharmacology. 27: 205-7. PMID 15602098 DOI: 10.1097/01.Wnf.0000144040.20600.C1 |
0.407 |
|
| 2004 |
Fernandez HH, Friedman JH, Lansang MC, Factor SA, Molho ES, Coskun DJ. Diabetes mellitus among parkinsonian patients treated chronically with clozapine. Parkinsonism & Related Disorders. 10: 439-41. PMID 15465403 DOI: 10.1016/J.Parkreldis.2004.04.007 |
0.38 |
|
| 2004 |
Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, ... ... Factor S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Archives of Neurology. 61: 1044-53. PMID 15262734 DOI: 10.1001/Archneur.61.7.1044 |
0.575 |
|
| 2004 |
Factor SA. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease. Neurology. 62: S12-7. PMID 15037666 DOI: 10.1212/Wnl.62.6_Suppl_4.S12 |
0.485 |
|
| 2004 |
Stacy M, Factor S. Rapid treatment of "off" episodes: Will this change Parkinson's disease therapy? Neurology. 62: S1-S2. DOI: 10.1212/Wnl.62.6_Suppl_4.S1 |
0.308 |
|
| 2003 |
Factor SA, Feustel PJ, Friedman JH, Comella CL, Goetz CG, Kurlan R, Parsa M, Pfeiffer R. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology. 60: 1756-61. PMID 12796526 DOI: 10.1212/01.Wnl.0000068010.82167.Cf |
0.397 |
|
| 2002 |
Factor SA, Jennings DL, Molho ES, Marek KL. The natural history of the syndrome of primary progressive freezing gait. Archives of Neurology. 59: 1778-83. PMID 12433266 DOI: 10.1001/Archneur.59.11.1778 |
0.4 |
|
| 2002 |
Reddy S, Factor SA, Molho ES, Feustel PJ. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Movement Disorders : Official Journal of the Movement Disorder Society. 17: 676-81. PMID 12210856 DOI: 10.1002/Mds.10176 |
0.448 |
|
| 2002 |
Factor SA, Molho ES, Friedman JH. Risperidone and Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 17: 221-2. PMID 11835472 DOI: 10.1002/Mds.1258 |
0.462 |
|
| 2001 |
Molho ES, Factor SA. Parkinson's disease: the treatment of drug-induced hallucinations and psychosis. Current Neurology and Neuroscience Reports. 1: 320-8. PMID 11898537 DOI: 10.1007/S11910-001-0085-8 |
0.424 |
|
| 2001 |
Frucht SJ, Fahn S, Greene PE, O'Brien C, Gelb M, Truong DD, Welsh J, Factor S, Ford B. The natural history of embouchure dystonia. Movement Disorders : Official Journal of the Movement Disorder Society. 16: 899-906. PMID 11746620 DOI: 10.1002/Mds.1167 |
0.313 |
|
| 2001 |
Factor SA, Molho ES, Feustel PJ, Brown DL, Evans SM. Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease. Clinical Neuropharmacology. 24: 295-9. PMID 11586115 DOI: 10.1097/00002826-200109000-00007 |
0.482 |
|
| 2001 |
Factor SA. Parkinson's Disease: Initial Treatment with Levodopa or Dopamine Agonists. Current Treatment Options in Neurology. 3: 479-493. PMID 11581525 DOI: 10.1007/S11940-001-0011-Z |
0.438 |
|
| 2001 |
Dewey RB, Hutton JT, LeWitt PA, Factor SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events Archives of Neurology. 58: 1385-1392. PMID 11559309 DOI: 10.1001/Archneur.58.9.1385 |
0.393 |
|
| 2001 |
Factor SA, Lava NS. Focal myopathy as a cause of anterocollis in Parkinsonism Movement Disorders. 16: 754-756. PMID 11481704 DOI: 10.1002/Mds.1152 |
0.37 |
|
| 2001 |
Weiner WJ, Factor SA, Jankovic J, Hauser RA, Tetrud JW, Waters CH, Shulman LM, Glassman PM, Beck B, Paume D, Doyle C. The long-term safety and efficacy of pramipexole in advanced Parkinson's disease. Parkinsonism & Related Disorders. 7: 115-120. PMID 11248592 DOI: 10.1016/S1353-8020(00)00031-6 |
0.628 |
|
| 2001 |
Factor SA, Friedman JH, Lannon MC, Oakes D, Bourgeois K. Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: Results of the 12 week open label extension in the PSYCLOPS trial Movement Disorders. 16: 135-139. PMID 11215574 DOI: 10.1002/1531-8257(200101)16:1<135::Aid-Mds1006>3.0.Co;2-Q |
0.479 |
|
| 2001 |
FRIEDMAN J, FERNANDEZ H, FACTOR S. Treatment of Psychosis in Parkinson's Disease Journal of the American Medical Directors Association. 2: 99-99. DOI: 10.1016/S1525-8610(04)70170-X |
0.456 |
|
| 2001 |
Friedman JH, Fernandez HH, Factor SA, Rangu S, Rowland FN. Treatment of psychosis in parkinson's disease (multiple letters) Journal of the American Medical Directors Association. 2: 99-100. |
0.353 |
|
| 2000 |
Weiner WJ, Factor SA. Ropinirole as compared with levodopa in Parkinson's disease. The New England Journal of Medicine. 343: 885. PMID 11001687 |
0.58 |
|
| 2000 |
Hiner BC, Earnhart M, Yamamoto T, Frucht S, Weiner WJ, Factor SA, Rascol O. Ropinirole as compared with levodopa in Parkinson's disease [1] (multiple letters) New England Journal of Medicine. 343: 884-885. PMID 11001685 DOI: 10.1056/NEJM200009213431211 |
0.578 |
|
| 2000 |
Hauser RA, Friedlander J, Zesiewicz TA, Adler CH, Seeberger LC, O'Brien CF, Molho ES, Factor SA. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia Clinical Neuropharmacology. 23: 75-81. PMID 10803796 DOI: 10.1097/00002826-200003000-00003 |
0.373 |
|
| 2000 |
Factor SA. The initial treatment of Parkinson's disease (multiple letters) Movement Disorders. 15: 360-362. PMID 10752599 DOI: 10.1002/1531-8257(200003)15:2<360::Aid-Mds1033>3.0.Co;2-N |
0.453 |
|
| 2000 |
Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in parkinson's disease Movement Disorders. 15: 201-211. PMID 10752567 DOI: 10.1002/1531-8257(200003)15:2<201::Aid-Mds1001>3.0.Co;2-D |
0.448 |
|
| 2000 |
Factor SA, Molho ES. Emergency department presentations of patients with Parkinson's disease American Journal of Emergency Medicine. 18: 209-215. PMID 10750935 DOI: 10.1016/S0735-6757(00)90023-8 |
0.476 |
|
| 2000 |
Factor SA, Brown DL, Molho ES. Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson's disease Movement Disorders. 15: 167-169. PMID 10634261 DOI: 10.1002/1531-8257(200001)15:1<167::Aid-Mds1029>3.0.Co;2-8 |
0.372 |
|
| 1999 |
Molho ES, Factor SA. Worsening of motor features of parkinsonism with olanzapine Movement Disorders. 14: 1014-1016. PMID 10584679 DOI: 10.1002/1531-8257(199911)14:6<1014::Aid-Mds1017>3.0.Co;2-9 |
0.414 |
|
| 1999 |
Factor SA, Molho ES. Transient benefit of amantadine in Parkinson's disease: The facts about the myth Movement Disorders. 14: 515-517. PMID 10348482 DOI: 10.1002/1531-8257(199905)14:3<515::Aid-Mds1024>3.0.Co;2-Z |
0.462 |
|
| 1999 |
Miyasaki JM, Grimes D, Lang AE, Factor SA, Molho ES, Brown DL. Acute delirium after withdrawal of amantadine in Parkinson's disease [5] (multiple letters) Neurology. 52: 1720-1721. PMID 10331717 DOI: 10.1212/Wnl.52.8.1717-D |
0.392 |
|
| 1998 |
Kompoliti K, Goetz CG, Boeve BF, Maraganore DM, Ahlskog JE, Marsden CD, Bhatia KP, Greene PE, Przedborski S, Seal EC, Burns RS, Hauser RA, Gauger LL, Factor SA, Molho ES, et al. Clinical presentation and pharmacological therapy in corticobasal degeneration Archives of Neurology. 55: 957-961. PMID 9678313 DOI: 10.1001/Archneur.55.7.957 |
0.374 |
|
| 1998 |
Molho ES, Feustel PJ, Factor SA. Clinical comparison of tardive and idiopathic cervical dystonia Movement Disorders. 13: 486-489. PMID 9613742 DOI: 10.1002/Mds.870130319 |
0.331 |
|
| 1998 |
Factor SA, Weiner WJ. 'Sleep benefit' in Parkinson's disease. Neurology. 50: 1514-5. PMID 9596032 |
0.494 |
|
| 1998 |
Factor SA, Molho ES, Brown DL. Acute delirium after withdrawal of amantadine in Parkinson's disease. Neurology. 50: 1456-8. PMID 9596005 DOI: 10.1212/WNL.50.5.1456 |
0.326 |
|
| 1998 |
Kieburtz K, Frey K, Albin R, Marek K, Bates G, Aylward E, Guttman M, Rouleau G, Baehr M, Pahwa R, Lyons KE, Wilkinson SB, Kieltyka J, Koller WC, Bertoni JM, ... ... Factor SA, et al. Twelfth Annual Symposia on Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Etiology, Pathogenesis, and Treatment of Huntington's Disease, Queen Elizabeth Hotel, Montreal, Canada, 18 October 1998 Movement Disorders. 13: 858-863. DOI: 10.1002/Mds.870130522 |
0.554 |
|
| 1997 |
Hauser RA, Zesiewicz TA, Factor SA, Guttman M, Weiner WJ. Clinical trials of add-on medications in Parkinson's disease: Efficacy versus usefulness. Parkinsonism & Related Disorders. 3: 1-6. PMID 18591048 DOI: 10.1016/S1353-8020(96)00042-9 |
0.553 |
|
| 1997 |
Factor SA, Barron KD. Mosaic pattern of gliosis in the neostriatum of a North American man with craniocervical dystonia and parkinsonism. Movement Disorders : Official Journal of the Movement Disorder Society. 12: 783-9. PMID 9380067 DOI: 10.1002/Mds.870120528 |
0.349 |
|
| 1997 |
Factor SA, Friedman JH. The emerging role of clozapine in the treatment of improvement disorders Movement Disorders. 12: 483-496. PMID 9251065 DOI: 10.1002/Mds.870120403 |
0.472 |
|
| 1997 |
Tarsy D, Kaufman D, Sethi KD, Rivner MH, Molho E, Factor S. An open-label study of botulinum toxin A for treatment of tardive dystonia Clinical Neuropharmacology. 20: 90-93. PMID 9037579 DOI: 10.1097/00002826-199702000-00012 |
0.359 |
|
| 1996 |
Podskalny GD, Factor SA. Chorea caused by lithium intoxication: A case report and literature review Movement Disorders. 11: 733-737. PMID 8914104 DOI: 10.1002/Mds.870110623 |
0.323 |
|
| 1995 |
Molho ES, Factor SA, Weiner WJ, Sanchez-Ramos JR, Singer C, Shulman L, Brown D, Sheldon C. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease. Journal of Neural Transmission. Supplementum. 45: 225-30. PMID 8748629 |
0.602 |
|
| 1995 |
Factor SA, Schneider AS. Peripheral catecholamine output in Parkinson's disease: Effects of drug treatment Experimental Neurology. 131: 64-68. PMID 7895813 DOI: 10.1016/0014-4886(95)90008-X |
0.406 |
|
| 1995 |
Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson's disease: drug-induced psychiatric states Advances in Neurology. 65: 115-138. PMID 7872135 |
0.307 |
|
| 1995 |
Factor SA, Molho ES, Brown DL. Combined clozapine and electroconvulsive therapy for the treatment of drug-induced psychosis in Parkinson's disease Journal of Neuropsychiatry and Clinical Neurosciences. 7: 304-307. PMID 7580188 DOI: 10.1176/Jnp.7.3.304 |
0.458 |
|
| 1995 |
Factor SA, Podskalny GD, Molho ES. Psychogenic movement disorders: Frequency, clinical profile, and characteristics Journal of Neurology, Neurosurgery and Psychiatry. 59: 406-412. PMID 7561921 DOI: 10.1136/Jnnp.59.4.406 |
0.337 |
|
| 1994 |
Factor SA, Ortof E, Dentinger MP, Mankes R, Barron KD. Platelet morphology in Parkinson's disease: an electron microscopic study. Journal of the Neurological Sciences. 122: 84-9. PMID 8195808 DOI: 10.1016/0022-510X(94)90056-6 |
0.406 |
|
| 1994 |
Factor SA, Brown D, Molho ES, Podskalny GD. Clozapine: A 2-year open trial in parkinson’s disease patients with psychosis Neurology. 44: 544-546. PMID 8145929 DOI: 10.1212/Wnl.44.3_Part_1.544 |
0.476 |
|
| 1994 |
Factor SA, Podskalny GD, Barron KD. Persistent neuroleptic-induced rigidity and dystonia in AIDS dementia complex: a clinico-pathological case report. Journal of the Neurological Sciences. 127: 114-20. PMID 7699386 DOI: 10.1016/0022-510X(94)90144-9 |
0.375 |
|
| 1993 |
Factor SA. Acetazolamide therapy of menstrual-related fluctuations in Parkinson's disease Movement Disorders. 8: 240-241. PMID 8474504 DOI: 10.1002/Mds.870080231 |
0.446 |
|
| 1993 |
Weiner WJ, Factor SA, Sanchez-Ramos JR, Singer C, Sheldon C, Cornelius L, Ingenito A. Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease. Neurology. 43: 21-7. PMID 8423888 DOI: 10.1212/Wnl.43.1_Part_1.21 |
0.622 |
|
| 1993 |
Factor SA, Weiner WJ. Early combination therapy with bromocriptine and levodopa in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 8: 257-62. PMID 8341289 DOI: 10.1002/Mds.870080302 |
0.625 |
|
| 1993 |
Factor SA, Weiner WJ. Combination therapy for PD Neurology. 43: 2726-2726. DOI: 10.1212/WNL.43.12.2726 |
0.504 |
|
| 1992 |
Factor SA, Brown D. Clozapine prevents recurrence of psychosis in Parkinson's disease Movement Disorders. 7: 125-131. PMID 1350059 DOI: 10.1002/Mds.870070205 |
0.484 |
|
| 1991 |
Factor SA, Weiner WJ. Prior history of head trauma in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 6: 225-9. PMID 1922127 DOI: 10.1002/Mds.870060306 |
0.532 |
|
| 1990 |
Factor SA, McAlarney T, Sanchez-Ramos JR, Weiner WJ. Sleep disorders and sleep effect in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 5: 280-5. PMID 2259351 DOI: 10.1002/Mds.870050404 |
0.586 |
|
| 1990 |
Factor SA, Sanchez-Ramos JR, Weiner WJ. Vitamin E therapy in Parkinson's disease. Advances in Neurology. 53: 457-61. PMID 2239484 |
0.524 |
|
| 1989 |
Sanchez-Ramos JR, Factor SA, Weiner WJ, Marquez J. Hemichorea-hemiballismus associated with acquired immune deficiency syndrome and cerebral toxoplasmosis. Movement Disorders : Official Journal of the Movement Disorder Society. 4: 266-73. PMID 2779596 DOI: 10.1002/Mds.870040308 |
0.487 |
|
| 1989 |
Factor SA, Weiner WJ, Hefti F. Acetaminophen metabolism by cytochrome P450 monooxygenases in Parkinson's disease. Annals of Neurology. 26: 286-8. PMID 2774516 DOI: 10.1002/Ana.410260219 |
0.592 |
|
| 1989 |
Weiner WJ, Factor SA, Sanchez-Ramos JR. The efficacy of (+)-4-propyl-9-hydroxynaphthoxazine as adjunctive therapy in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 52: 732-5. PMID 2746265 DOI: 10.1136/Jnnp.52.6.732 |
0.544 |
|
| 1989 |
Factor SA, Sanchez-Ramos JR, Weiner WJ, Ingenito AM. Efficacy of sinemet CR4 in subgroups of patients with Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 52: 83-8. PMID 2709040 DOI: 10.1136/Jnnp.52.1.83 |
0.589 |
|
| 1989 |
Factor SA, Weiner WJ. Retrospective evaluation of vitamin E therapy in Parkinson's disease Annals of the New York Academy of Sciences. 570: 441-442. DOI: 10.1111/J.1749-6632.1989.Tb14951.X |
0.572 |
|
| 1988 |
Factor SA, Sanchez-Ramos JR, Weiner WJ. Parkinson's disease: an open label trial of pergolide in patients failing bromocriptine therapy. Journal of Neurology, Neurosurgery, and Psychiatry. 51: 529-33. PMID 3288717 DOI: 10.1136/Jnnp.51.4.529 |
0.599 |
|
| 1988 |
Factor SA, Sanchez-Ramos JR, Weiner WJ. Cocaine and Tourette's syndrome. Annals of Neurology. 23: 423-4. PMID 3164176 DOI: 10.1002/Ana.410230431 |
0.455 |
|
| 1988 |
Factor SA, Sanchez-Ramos J, Weiner WJ. Delayed-onset dystonia associated with corticospinal tract dysfunction. Movement Disorders : Official Journal of the Movement Disorder Society. 3: 201-10. PMID 3057351 DOI: 10.1002/Mds.870030304 |
0.503 |
|
| 1988 |
Factor SA, Sanchez-Ramos J, Weiner WJ. Trauma as an etiology of parkinsonism: a historical review of the concept. Movement Disorders : Official Journal of the Movement Disorder Society. 3: 30-6. PMID 3050470 DOI: 10.1002/Mds.870030105 |
0.603 |
|
| 1987 |
Weiner WJ, Factor SA, Sanchez-Ramos J, Berger J. A double-blind evaluation of ciladopa in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 2: 211-7. PMID 3332914 DOI: 10.1002/Mds.870020308 |
0.549 |
|
| 1987 |
Sanchez-Ramos JR, Factor SA, Weiner WJ. Paraquat and Parkinson's disease Neurology. 37: 1820-1820. DOI: 10.1212/WNL.37.11.1820-a |
0.572 |
|
| Show low-probability matches. |